17/09/2025 22:11
                        |
                        Medical, Health & Aged Care
                    
                    
                        
*	Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)
*	Results highlight the potential of MAVENCLAD to reduce neurodegeneration...